Cite
HARVARD Citation
Tison, F. et al. (2016). A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's Disease. Movement disorders. 31 (9), pp. 1373-1380. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Tison, F. et al. (2016). A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's Disease. Movement disorders. 31 (9), pp. 1373-1380. [Online].